Product
TU2218 + Pembrolizumab
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01